Drug Target Review

SEPTEMBER 20, 2023

Author bio: Matthew Habgood Principal Computational Chemist, Cresset Matthew graduated from Imperial College London in 2004 with an MSci in Chemistry and was co-awardee of the Neil Arnott prize for best chemistry graduate at the University of London. Previous roles include CEO of Amedis and VP, Europe at CambridgeSoft.

Drugs 105

Drugs Metabolic Stability Computational Chemistry Pharmaceuticals 105

Sygnature Discovery

MARCH 24, 2022

When DMPK scientist Lynette Ongeri joined Sygnature this month, she unknowingly helped us reach a landmark we couldn’t be prouder of… Sygnature Discovery – or Sygnature Chemical Services Ltd, as it was known then – opened its doors in 2004 with five colleagues.

Computational Chemistry 52

Computational Chemistry International Science Pharmaceuticals 52

Sygnature Discovery

JULY 31, 2023

Leading integrated drug discovery partner, Sygnature Discovery (“Sygnature”) has announced its acquisition of one of North America’s largest discovery Contract Research Organisations, Canada-based NuChem Sciences. Its staff of over 1,000, which includes 900 scientists, partners with global pharma, biotech and NFP organisations.

Computational Chemistry 52

Computational Chemistry Science Clinical Trials Pharmaceutical Companies 52